Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the revenue sharing agreement, Neopharm gains exclusive rights to commercialize QRX003 in Israel. Quoin will be the exclusive supplier of QRX003 to Neopharm.
Lead Product(s): QRX003
Therapeutic Area: Rare Diseases and Disorders Product Name: QRX003
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Quoin Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 17, 2022